MindWalk Holdings Launches ReefIQ™ Biological Context Layer for AI Drug Discovery

On June 10, 2026, MindWalk Holdings Corp. (NASDAQ: HYFT) announced the launch of ReefIQ™, a biological context layer designed for AI-enabled drug discovery and biologics development. ReefIQ serves as an intermediary layer between fragmented client discovery data and AI reasoning workflows, utilizing the company's proprietary HYFT® technology. The system harmonizes various data types—including sequences, structures, assay outputs, and literature—into a governed, queryable biological context. The company's architecture now consists of three primary layers: HYFT (biological representation), ReefIQ (context organization and governance), and LensAI™ (reasoning and application). By preserving both positive and negative results as governed knowledge, ReefIQ aims to provide a compounding data advantage for pharmaceutical programs. CEO Dr. Jennifer Bath emphasized that the platform makes AI reasoning more trustworthy in regulated settings. MindWalk confirmed that LensAI is currently generating recurring revenue through existing contracts with life-sciences customers, and ReefIQ is intended to be the foundation for all future engagements.